Rigel Pharmaceuticals RIGL Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.
The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year five).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's finite-lived intangible assets - expected amortization expense (year five)?
- Rigel Pharmaceuticals (RIGL) reported finite-lived intangible assets - expected amortization expense (year five) of $12.99M in Q4 2025.
- What does finite-lived intangible assets - expected amortization expense (year five) mean?
- This represents the projected non-cash expense related to the consumption of intangible assets in the fifth year following the reporting date. It provides visibility into the long-term impact of past acquisitions or intellectual property development on future earnings. This metric is essential for modeling long-term profitability and cash flow sustainability.